Sho Oasa, Wai H Mak, Adam L Maddox, Carinna Lima, Andras Saftics, Lars Terenius, Tijana Jovanović-Talisman, Vladana Vukojević
{"title":"乙醇和阿片受体拮抗剂纳曲酮和LY2444296对富含胆固醇和鞘磷脂的质膜结构域组织的影响","authors":"Sho Oasa, Wai H Mak, Adam L Maddox, Carinna Lima, Andras Saftics, Lars Terenius, Tijana Jovanović-Talisman, Vladana Vukojević","doi":"10.1021/acschemneuro.5c00596","DOIUrl":null,"url":null,"abstract":"<p><p>Excessive consumption of alcohol (ethanol (EtOH)) can lead to alcohol use disorder (AUD). While AUD can be managed through behavioral interventions, there is a great need for pharmacological remedies for this condition. To date, only three pharmacotherapeutic treatments for AUD have been approved by both the U.S. Food and Drug Administration and the European Medicines Agency. This is partly due to an incomplete understanding of the intricate molecular mechanisms through which EtOH affects cellular functions. Here, we focus on EtOH effects on nanoscale organization and the lateral dynamics of molecules in the plasma membrane, the primary cellular component that is affected by this compound. In a cell culture model natively expressing opioid receptors, important targets for medications aimed at preventing relapses in AUD, we used methods with single-molecule sensitivity to characterize the lateral organization and dynamics of cholesterol (Chol)- and sphingomyelin (SM)-enriched domains. Our data reveal that EtOH triggered a reorganization of Chol/SM-enriched domains and increased the plasma membrane fluidity. The general opioid receptor antagonist naltrexone (NTX), approved for relapse prevention in AUD, caused reorganization of Chol/SM-enriched domains, while pretreatment with NTX warded off EtOH-induced plasma membrane reorganization. In contrast, the selective kappa-opioid receptor antagonist LY2444296, at concentrations tested, showed a modest effect on Chol/SM-enriched domain organization and did not protect against EtOH-induced changes in plasma membrane organization. While the significance of these findings for AUD treatment remains uncertain at this stage, our study reveals that the action of NTX is not only limited to blocking opioid receptor activity by preventing agonist binding to the orthosteric binding site, but also is protective against short- and long-range EtOH-induced plasma membrane reorganization. By protecting against EtOH-induced changes in the lateral organization and dynamics of lipids in the plasma membrane, NTX may affect physiological outcomes through previously unrecognized noncanonical mechanisms.</p>","PeriodicalId":13,"journal":{"name":"ACS Chemical Neuroscience","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of Ethanol and Opioid Receptor Antagonists Naltrexone and LY2444296 on the Organization of Cholesterol- and Sphingomyelin-Enriched Plasma Membrane Domains.\",\"authors\":\"Sho Oasa, Wai H Mak, Adam L Maddox, Carinna Lima, Andras Saftics, Lars Terenius, Tijana Jovanović-Talisman, Vladana Vukojević\",\"doi\":\"10.1021/acschemneuro.5c00596\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Excessive consumption of alcohol (ethanol (EtOH)) can lead to alcohol use disorder (AUD). While AUD can be managed through behavioral interventions, there is a great need for pharmacological remedies for this condition. To date, only three pharmacotherapeutic treatments for AUD have been approved by both the U.S. Food and Drug Administration and the European Medicines Agency. This is partly due to an incomplete understanding of the intricate molecular mechanisms through which EtOH affects cellular functions. Here, we focus on EtOH effects on nanoscale organization and the lateral dynamics of molecules in the plasma membrane, the primary cellular component that is affected by this compound. In a cell culture model natively expressing opioid receptors, important targets for medications aimed at preventing relapses in AUD, we used methods with single-molecule sensitivity to characterize the lateral organization and dynamics of cholesterol (Chol)- and sphingomyelin (SM)-enriched domains. Our data reveal that EtOH triggered a reorganization of Chol/SM-enriched domains and increased the plasma membrane fluidity. The general opioid receptor antagonist naltrexone (NTX), approved for relapse prevention in AUD, caused reorganization of Chol/SM-enriched domains, while pretreatment with NTX warded off EtOH-induced plasma membrane reorganization. In contrast, the selective kappa-opioid receptor antagonist LY2444296, at concentrations tested, showed a modest effect on Chol/SM-enriched domain organization and did not protect against EtOH-induced changes in plasma membrane organization. While the significance of these findings for AUD treatment remains uncertain at this stage, our study reveals that the action of NTX is not only limited to blocking opioid receptor activity by preventing agonist binding to the orthosteric binding site, but also is protective against short- and long-range EtOH-induced plasma membrane reorganization. By protecting against EtOH-induced changes in the lateral organization and dynamics of lipids in the plasma membrane, NTX may affect physiological outcomes through previously unrecognized noncanonical mechanisms.</p>\",\"PeriodicalId\":13,\"journal\":{\"name\":\"ACS Chemical Neuroscience\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Chemical Neuroscience\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acschemneuro.5c00596\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Chemical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acschemneuro.5c00596","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
过量饮酒(乙醇)可导致酒精使用障碍(AUD)。虽然AUD可以通过行为干预来管理,但对于这种情况,非常需要药物治疗。迄今为止,美国食品和药物管理局和欧洲药品管理局仅批准了三种治疗AUD的药物治疗方法。这部分是由于对EtOH影响细胞功能的复杂分子机制的理解不完全。在这里,我们专注于EtOH对纳米级组织和质膜分子横向动力学的影响,质膜是受该化合物影响的主要细胞成分。在原生表达阿片受体的细胞培养模型中,我们使用单分子敏感性方法来表征胆固醇(Chol)和鞘磷脂(SM)富集区域的横向组织和动力学。阿片受体是预防AUD复发的重要药物靶点。我们的数据显示,EtOH引发了Chol/ sm富集结构域的重组,并增加了质膜的流动性。一般的阿片受体拮抗剂纳曲酮(NTX)被批准用于预防AUD复发,引起Chol/ sm -富集结构域的重组,而NTX预处理可以防止etoh诱导的质膜重组。相比之下,选择性kappa-阿片受体拮抗剂LY2444296,在测试浓度下,对Chol/ sm -富集结构域的组织表现出适度的影响,并且对etoh诱导的质膜组织变化没有保护作用。虽然这些发现对AUD治疗的意义目前尚不确定,但我们的研究表明,NTX的作用不仅限于通过阻止激动剂与正位结合位点的结合来阻断阿片受体的活性,而且还可以保护etoh诱导的短期和长期质膜重组。通过防止etoh诱导的质膜内脂质横向组织和动态变化,NTX可能通过以前未被认识的非规范机制影响生理结果。
Effects of Ethanol and Opioid Receptor Antagonists Naltrexone and LY2444296 on the Organization of Cholesterol- and Sphingomyelin-Enriched Plasma Membrane Domains.
Excessive consumption of alcohol (ethanol (EtOH)) can lead to alcohol use disorder (AUD). While AUD can be managed through behavioral interventions, there is a great need for pharmacological remedies for this condition. To date, only three pharmacotherapeutic treatments for AUD have been approved by both the U.S. Food and Drug Administration and the European Medicines Agency. This is partly due to an incomplete understanding of the intricate molecular mechanisms through which EtOH affects cellular functions. Here, we focus on EtOH effects on nanoscale organization and the lateral dynamics of molecules in the plasma membrane, the primary cellular component that is affected by this compound. In a cell culture model natively expressing opioid receptors, important targets for medications aimed at preventing relapses in AUD, we used methods with single-molecule sensitivity to characterize the lateral organization and dynamics of cholesterol (Chol)- and sphingomyelin (SM)-enriched domains. Our data reveal that EtOH triggered a reorganization of Chol/SM-enriched domains and increased the plasma membrane fluidity. The general opioid receptor antagonist naltrexone (NTX), approved for relapse prevention in AUD, caused reorganization of Chol/SM-enriched domains, while pretreatment with NTX warded off EtOH-induced plasma membrane reorganization. In contrast, the selective kappa-opioid receptor antagonist LY2444296, at concentrations tested, showed a modest effect on Chol/SM-enriched domain organization and did not protect against EtOH-induced changes in plasma membrane organization. While the significance of these findings for AUD treatment remains uncertain at this stage, our study reveals that the action of NTX is not only limited to blocking opioid receptor activity by preventing agonist binding to the orthosteric binding site, but also is protective against short- and long-range EtOH-induced plasma membrane reorganization. By protecting against EtOH-induced changes in the lateral organization and dynamics of lipids in the plasma membrane, NTX may affect physiological outcomes through previously unrecognized noncanonical mechanisms.
期刊介绍:
ACS Chemical Neuroscience publishes high-quality research articles and reviews that showcase chemical, quantitative biological, biophysical and bioengineering approaches to the understanding of the nervous system and to the development of new treatments for neurological disorders. Research in the journal focuses on aspects of chemical neurobiology and bio-neurochemistry such as the following:
Neurotransmitters and receptors
Neuropharmaceuticals and therapeutics
Neural development—Plasticity, and degeneration
Chemical, physical, and computational methods in neuroscience
Neuronal diseases—basis, detection, and treatment
Mechanism of aging, learning, memory and behavior
Pain and sensory processing
Neurotoxins
Neuroscience-inspired bioengineering
Development of methods in chemical neurobiology
Neuroimaging agents and technologies
Animal models for central nervous system diseases
Behavioral research